Biologics use by rheumatoid arthritis patients was associated with a 25% reduction in the risk of premature death, compared to patients without exposure to biologics, based on data from a population-based study of more than 4,000 patients. Dr. Diane Lacaille of the Arthritis Research Center of Canada discusses the results at the American College of Rheumatology's annual meeting.